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Affibody molecules specific for H-Ras and Raf-1 were evaluated for their ability to inhibit synovial cell function.
Affibody molecules targeting H-Ras (Zras122, Zras220, and Zras521) or Raf-1 (Zraf322) were introduced into the MH7A
synovial cell line using two delivery methods: transfection with plasmids encoding the affibody molecules or direct
introduction of affibody protein using a cell-penetrating peptide reagent. Interleukin-6 (IL-6) and prostaglandin E2
(PGE2) production by MH7A cells were analyzed by enzyme-linked immunosorbent assay after stimulation with tumor
necrosis factor-alpha (TNF-α). Cell proliferation was also analyzed. Phosphorylation of extracellular signal-regulated
kinase (ERK) was analyzed by western blot. All affibody molecules could inhibit IL-6 and PGE2 production in
TNF-α-stimulated MH7A cells. The inhibitory effect was stronger when affibody molecules were delivered as proteins
via a cell-penetrating peptide reagent than when plasmid-DNA encoding the affibody moelcules was transfected into
the cells. Plasmid-expressed Zras220 inhibited phosphorylation of ERK in TNF-α-stimulated MH7A cells. Protein-introduced
Zraf322 inhibited the production of IL-6 and PGE2 and inhibited cell proliferation in MH7A cells. These findings suggest
that affibody molecules specific for H-Ras and Raf-1 can affect intracellular signal transduction through the MAP kinase
pathway to inhibit cell proliferation and production of inflammatory mediators by synovial cells.
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Rheumatoid arthritisIntroduction
Rheumatoid arthritis (RA) is an inflammatory disease
characterized by the progressive destruction of joints. In
RA, hyperplasia of synovial lining cells is observed along
with angiogenesis and inflammatory mononuclear cell
infiltration (Kitano et al. 2006). A wide variety of mole-
cules produced by both synovial cells and infiltrating
inflammatory mononuclear cells is thought to be in-
volved in RA pathology. Specifically, proinflammatory
cytokines such as interleukin-6 (IL-6), IL-17 (Schlegel
et al. 2013) and tumor necrosis factor alpha (TNF-α)
play a key role in RA pathogenesis, including the activa-
tion of synovial fibroblasts, osteoclasts, and inflammatory
mononuclear cells, which results in irreversible damage to
the soft tissues and bones (Olsen and Stein 2004).* Correspondence: seiji@huhs.ac.jp
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in any medium, provided the original work is pOne of the conventional disease-modifying antirheu-
matic drugs (DMARDs), methotrexate, is the standard
for RA pharmacotherapy (Upchurch and Kay 2012).
However, its treatment outcomes are not satisfactory
and often cause high levels of toxicity and adverse effects
for patients (Smolen and Steiner 2003). In recent years,
various biological agents have been developed and used
clinically as important options for RA treatment (Saag
et al. 2008). These biological agents include an anti-
CD20 antibody (rituximab) (Mélet et al. 2013), TNF
antagonists (e.g., adalimumab, etanercept, golimumab, and
infliximab), an IL-6 receptor antagonist (tocilizumab)
(Smolen and Aletaha 2011), and a recombinant fusion
protein consisting of the extracellular domain of human
CTLA-4 (abatacept) (Gómez-Reino 2012). Although these
biological agents provide favorable treatment outcomes
for RA patients, in view of medical economics, biological
therapies are more costly than traditional DMARDs. Thus,s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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healthcare payers and providers are conscious of cost in
light of the current period of budget constraints (Furneri
et al. 2012).
Several biologically active, non-immunoglobulin-based
proteins have been created as candidates of novel bio-
logical agents. For instance, a monobody is a target-
binding protein that is generated from the fibronectin
type III domain (Koide et al. 2012). Synthetic ankyrin
repeat proteins have a binding scaffold and are potential
diagnostic and therapeutic tools (Baumann et al. 2007).
In this study, we investigated another class of non-
immunoglobulin ligands, referred to as affibody molecules.
They are engineered binding proteins based on a scaf-
fold of the three-α-helix bundle Z-domain (Friedman
and Ståhl 2009; Nilsson and Tolmachev 2007; Nygren
2008). The 6-kDa Z-domain is derived from the B-domain,
one of the five domains in Staphylococcus aureus protein A
(Gunneriusson et al. 1996).
Affibody molecules associated with signal transduction
or transcription in tumor development or immune re-
sponses have been screened and applied. For example,
affibody molecules against c-Jun, an oncogenic tran-
scription factor, have been selected and are able to
detect c-Jun in a melanoma cell line (Lundberg et al.
2009). Furthermore, other affibody molecules against
human epidermal growth factor receptor (HER), spe-
cifically HER2 (Lindberg et al. 2012) and HER3 (Malm
et al. 2013), have been investigated.
We have previously reported the selection of H-Ras-
binding or Raf-1-binding affibody molecules (Grimm
et al. 2010). Affibody clones Zras122, Zras220, and Zraf322
were isolated by phage display selection from a library,
and the specificity and affinity for H-Ras or Raf-1 pro-
teins were determined in that study. Each molecule was
demonstrated to selectively bind Ras or Raf-1 proteins,
but not other human control proteins. Zras122, Zras220,
and Zraf322 had binding affinities in the high nanomolar
to low micromolar range, as demonstrated by a real-
time biospecific interaction analysis. As an alternative
or complement to current RA treatment regimens,
these affibody molecules might have the potential to
inhibit signal transduction mediated by Ras and Raf, since
this signaling is thought to be important for efficient
synthesis of several inflammatory mediators (Yamamoto
et al. 2003).
In this study, we investigated the effect of introducing
H-Ras-binding and Raf-1-binding affibody molecules in
the MH7A synovial cell line (Tsunemi et al. 2010). First,
we subcloned DNA encoding affibody molecules against
H-Ras or Raf-1 into a plasmid DNA vector for mamma-
lian expression, and the vectors were introduced into
MH7A cells. Then, affibody proteins were produced using
an Escherichia coli expression system and were introducedinto MH7A cells. We investigated inhibition caused by
H-Ras- or Raf-1-targeting affibody molecules on the
production of the inflammatory mediators IL-6 and
prostaglandin E2 (PGE2). Furthermore, we examined
proliferation of MH7A cells.
Materials and methods
Cell line
The human MH7A synovial cell line (Riken, Saitama,
Japan), which originated from intra-articular soft tissue of
the knee joints of an RA patient, was established by trans-
fection with the SV40 T antigen (Miyazawa et al. 1998).
MH7A cells were cultured in RPMI 1640 (Sigma, St.
Louis, MO, USA) containing 10% heat-inactivated fetal
bovine serum (Whittaker, Walkersville, MD, USA), 100
units/mL of penicillin, and 100 μg/mL of streptomycin
(Invitrogen, CA, USA) at 37°C in an atmosphere of 5%
CO2 in air.
Plasmid construction for affibodies and introduction into
MH7A cells
The plasmids that were used to produce affibodies in
mammalian cells were constructed by first amplifying
DNA encoding anti-H-Ras and anti-Raf-1 affibodies
(Zras122, Zras220, Zras521, and Zraf322) by PCR using primers
5′-AAGGGGATCCACCATGGGCAGCAGCCATCATCA
TCA-3′ and 5′-AGGGGTTATGCTAGTTATTGCTCAG
CGCGGAATTCTTA-3′ (Grimm et al. 2010). DNA se-
quences of affibody molecules are listed the additional file
(Additional file 1). Each fragment was inserted into the
multiple cloning site of pcDNA3.1(+) (Invitrogen). The
nucleotide sequences of these constructs were con-
firmed by sequencing with an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
Constructs were introduced into MH7A cells for transi-
ent expression using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s instructions. Cells used
for transfection were seeded at 1.7 × 105 cells/well in a
24-well plate (BD, Franklin Lakes, NJ, USA) and cul-
tured for 1 d before transfection.
Western blot analysis of affibody expression
MH7A cells transfected with affibody-encoding plasmids
(1 × 107) were plated in a 24-well plate. After 48 or 72 h
of incubation, cells were lysed in Mammalian Lysis
Buffer from the Qproteome Mammalian Protein Prep
Kit (Qiagen, Hilden, Germany), and protein content was
determined using the Bio-Rad Protein Assay Reagent
(Bio-Rad, Hercules, CA, USA) with bovine serum albu-
min as the standard. Each sample was resolved by SDS-
PAGE on 20% polyacrylamide gels and then transferred
to 0.45-μm nitrocellulose membranes. After blocking
overnight at 4°C with Blocking One Solution (Nacalai
Tesque, Kyoto, Japan), membranes were incubated with
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Cambridge, UK) as the primary antibody (1:400 dilution
in phosphate-buffered saline; PBS) overnight at 4°C.
After washing the membranes with Tris-buffered sa-
line–0.05% Tween 20 (washing buffer), target proteins
were detected with alkaline phosphatase (AP)-labeled
ReserveAP Rabbit anti-goat immunoglobulin G (IgG)
(KPL, Gaithersburg, MD, USA; 1:1,000 dilution in 1%
PBS containing 0.05% Tween 20). NBT/BCIP (Roche,
Mannheim, Germany) was used as the AP colorimetric
substrate for visualization.
Measurement of IL-6 or PGE2 levels
MH7A cells (2 × 104) that were transfected with an
affibody-encoding plasmid were plated in a 24-well plate
and cultured in the presence or absence of 100 ng/mL
TNF-α. After 24 or 48 h of incubation, IL-6 and PGE2
levels were determined by assaying supernatants with an
Enzyme-Linked Immunosorbent Assay (ELISA) Kit for
IL-6 (R&D Systems, Minneapolis, MN, USA) or PGE2
(ENZO Life Sciences, Farmingdale, NY, USA), respect-
ively, according to the instructions.
Cell proliferation studies
Cell viability was determined using a Cell Counting Kit
(CCK)-8 (Dojindo, Kumamoto, Japan), in which 2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
fophenyl)-2H-tetrazolium monosodium salt was used
as a substrate (Ohuchida et al. 2004). Absorbance was
measured using a SpectraMax M2 Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA) at 450 nm
(Shibasaki et al. 2012).
Western blot analysis for phosphorylated extracellular
signal-regulated kinase (p-ERK)
Western blot analysis was performed as described above.
Briefly, MH7A cells transfected with affibody-encoding
plasmids (1 × 107) were plated in a 24-well plate, incu-
bated for 24 h, and then stimulated with 100 ng/mL
TNF-α (Sigma). After an additional incubation of 16 or
24 h, the soluble fraction of the cells was analyzed by
western blot analysis using IgG against p-ERK (Santa
Cruz Biotechnology, Dallas, TX, USA) as a primary anti-
body. Goat polyclonal IgG against actin (Santa Cruz)
was used as a control.
Affibody protein production in E. coli
Expression of the pAffi-Zras122, −Zras220, −Zras521, and
-Zraf322 plasmids in E. coli BL21(DE3) produced H-Ras and
Raf-1 affibody molecules with an N-terminal 6 ×His tag.
The E. coli cells were inoculated in 2 mL of Luria-Bertani
(LB) broth containing 100 μg/L ampicillin and were incu-
bated in a shaking incubator overnight at 37°C. The 2-mL
overnight cultures were used to inoculate fresh LB mediumcontaining 100 μg/L ampicillin (125 mL), and cultures
were grown at 37°C to an OD600 of 0.6–0.7. Gene ex-
pression was then induced by the addition of isopropyl
β-D-thiogalactoside (Wako Pure Chemical, Osaka, Japan)
to a final concentration of 1 mM. After 3–4 h of incuba-
tion at 37°C, the cells were harvested by centrifugation
(4,000× g, 15 min, 4°C). The cell pellets were subsequently
resuspended in 10 mL of B-PER Bacterial Protein Extrac-
tion Reagent (Thermo Fisher Scientific, Waltham, MA,
USA) and shaken gently for 10 min at room temperature
(25°C). Cell debris was pelleted by centrifugation at
27,000 × g for 20 min. Supernatants containing soluble
proteins were purified by recovering the 6 × His-
Zras122, −Zras220, −Zras521, and -Zraf322 fusion proteins
after passage through nickel-chelated agarose columns
(Thermo Fisher Scientific). The columns were equilibrated
with 10 mL of B-PER Bacterial Protein Extraction Reagent
before application of the supernatant. After washing
the column with B-PER wash buffer, the bound pro-
teins were released with elution buffer (50 mM Tris,
300 mM NaCl, 200 mM imidazole, 10% [v/v] glycerol),
according to a previous protocol (Shibasaki et al. 2013).
The concentration of each protein was determined by
the BCA assay (REF), and the molecular size was con-
firmed by SDS-PAGE.
Affibody protein introduction into MH7A cells
MH7A cells were seeded at 1.7 × 105 cells/well in a 24-well
plate and cultured for 1 d before the introduction of
the purified proteins. Each affibody protein (5 μg) was
mixed with Xfect Protein Buffer (Takara Bio, Shiga,
Japan) to a total volume to 20 μL and then mixed with
Xfect Protein Transfection Reagent. As a negative con-
trol, PBS was used in the place of the affibody molecule.
After substitution of culture medium with serum-free
medium for the cells, a diluted protein mixture was added
to cultured MH7A cells and incubated at 37°C, according
to a previous protocol (Kato et al. 2013).
Statistical analysis
Results are expressed as the mean ± SD. The significance
of the difference between the experimental results and
control values was determined by Student’s t-test. P values
less than 0.05 were considered significant.
Results
Expression of affibody molecules in MH7A cells
Each pcDNA3.1-based plasmid encoding Zras122, Zras220,
or Zras521 was designed to yield head-to-tail homodimers
of the molecules. The plasmid encoding Zraf322 was de-
signed to yield a monomeric molecule. Each plasmid
was introduced into MH7A cells, and protein expression
was confirmed by western blot analysis. The dimeric affi-
body molecules, Zras122, Zras220, and Zras521, appeared to
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molecule, Zraf322, appeared to be approximately 6 kDa.
The Zras122 affibody protein was expressed in a greater
quantity than the other affibody proteins at 48 and 72 h
after transfection (Figure 1).Inhibition of IL-6 and PGE2 production by plasmid-
expressed affibody proteins
Each plasmid expressing the affibody molecules was in-
troduced into MH7A cells to observe any inhibition of
IL-6 production. At 24 h after transfection, TNF-α was
added to induce synthesis of IL-6 and PGE2 (Figure 1A).
After an additional 24–48 h of culture, the supernatant
was collected, and IL-6 production was evaluated by
ELISA. Zras220 reduced IL-6 production by approxi-
mately 20% relative to the empty plasmid (pcDNA3.1)
at 24 and 48 h after TNF-α stimulation; in contrast,
expression of Zraf322 reduced IL-6 production by ap-
proximately 10% (Figure 2A). The inhibition of IL-6
production by each plasmid-expressed affibody was
greater at 24 h than at 48 h after TNF-α stimulation
(Figure 2A). Possible inhibition of PGE2 production in
MH7A cells was also analyzed upon expression of the
affibody molecules. Expression of Zraf322 reduced PGE2
production by approximately 10% relative to the empty
plasmid at 24 h after TNF-α stimulation, while expres-
sion of Zraf122. Zras220, and Zras521 did not significantlyA
B
Figure 1 Experimental protocol (A) and western blot analysis for con
Affibody molecules were introduced into MH7A cells encoded by DNA or
(100 ng/mL) and cultured for an additional 24–48 h. (B) Western blot analys
affibody protein molecules was analyzed at 48 and 72 h after the introd
a control.affect PGE2 expression at 24 h (Figure 2B). Zras122 and
Zraf322 reduced PGE2 production by approximately
20% relative to the control plasmid at 48 h after TNF-α
stimulation; in contrast to IL-6 production, the inhib-
ition of PGE2 production by each plasmid-expressed
affibody was greater at 48 h than at 24 h after TNF-α
stimulation (Figure 2B).Phosphorylation of ERK
ERK1/2 is situated downstream of Ras/Raf in the MAP
kinase signal transduction cascade. To determine if affi-
body molecules affected signaling through this pathway,
phosphorylation of ERK1/2 was evaluated in MH7A
cells at 16 and 24 h after TNF-α stimulation. Western
blot analysis of each cell lysate was performed, using an
anti-p-ERK antibody with an anti-actin antibody serving
as a control. The expression of Zras220 inhibited phos-
phorylation of ERK1/2 at 16 h after TNF-α stimulation
(Figure 3). This result indicated that Zras220, but not the
other affibody proteins, was able to block ERK1/2 phos-
phorylation through binding to Ras.Inhibition of IL-6 and PGE2 production by affibody
molecules as proteins in MH7A cells
The affibody molecules were expressed in Escherichia
coli and purified to >95% purity. SDS-PAGE analysis
of the fractions from the last chromatographic stepfirmation of cytosolic synthesis of affibody molecules (B). (A)
as proteins. After 24-h culture, the cells were stimulated with TNF-α
is of each soluble fraction from MH7A cells harboring plasmid-encoded
uction of the plasmid into MH7A cells. Actin was analyzed as
Figure 2 IL-6 (A) and PGE2 (B) production by MH7A cells with plasmid-expressed affibodies. MH7A cells were transfected with plasmids
encoding affibodies. After 24 h of culture, the cells were stimulated with TNF-α (100 ng/mL) and cultured for an additional 24–48 h. Data represent the
percent inhibition of IL-6 or PGE2 production by MH7A cells. Percent inhibition was calculated as follows: ([(IL-6 or PGE2 levels in MH7A cells transfected
with affibody DNA) – (IL-6 or PGE2 levels in MH7A cells transfected with pcDNA3.1)]/[IL-6 or PGE2 levels in MH7A cells transfected with pcDNA3.1]) × 100.
Data represent the means ± SD of three independent experiments. *p <0.05.
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molecular weight (data not shown). Individually, Zras122,
Zras220, Zras521, and Zraf322 proteins were introduced into
MH7A cells by incubation with the cell-penetrating
peptide reagent Xfect. Although the inhibition of IL-6Figure 3 Western blot analysis for the confirmation of ERK1/2
phosphorylation. MH7A cells were transfected with plasmids
encoding affibodies. After 24 h of culture, the cells were stimulated
with TNF-α (100 ng/mL) and cultured for an additional 24–48 h. Each
soluble fraction of MH7A cells harboring plasmid-encoded affibody
molecules was analyzed via western blot for the expression of p-ERK
and actin at 16 and 24 h after TNF-α stimulation. Representative data
are shown for p-ERK and actin expression by MH7A cells.production by Zras122 was stronger than the inhibition
by the other proteins at 24 h, Zras220 protein strongly
inhibited IL-6 production by approximately 46% relative
to the control penetrating peptide alone at 48 h after
TNF-α stimulation (Figure 4A). The Zras220 protein also
strongly inhibited PGE2 production by 32% relative to
the control penetrating peptide alone at 48 h after TNF-
α stimulation (Figure 4B).
Effect of affibody molecules on cell proliferation
The proliferation of MH7A cells was also investigated
upon expression of the affibody molecules by plasmid
transfection. No change in proliferation could be observed
at 24 or 48 h after TNF-α stimulation for any of the
constructs, compared to the cells harboring the empty
plasmid (Figure 5A). We next investigated a possible
effect on MH7A cell proliferation after introduction of
affibody proteins. MH7A cells transfected with a control
peptide proliferated 151% from 0–24 h, while those
transfected with Zraf322 proteins proliferated almost 0%
from 0–24 h (Figure 5B). Furthermore, during 0–48 h,
control cells and Zraf322 proteins-transfected cells prolif-
erated 327% and 291%, respectively. These results indi-
cate an inhibitory effect of Zraf322 protein introduction
on proliferation.
A B
Figure 4 IL-6 (A) and PGE2 (B) production by affibody protein-introduced MH7A cells. MH7A cells were transfected with affibody proteins.
After 24 h of culture, the cells were stimulated with TNF-α (100 ng/mL) and cultured for an additional 24–48 h. IL-6 and PGE2 levels were analyzed,
and percent inhibition of IL-6 or PGE2 production was determined. Percent inhibition was calculated as follows: ([(IL-6 or PGE2 levels in affibody
protein-introduced MH7A cells) – (IL-6 or PGE2 levels in MH7A cells introduced with standard peptides)]/([IL-6 or PGE2 levels in MH7A cells introduced
with standard peptides]) × 100. Data represent the means ± SD of three independent experiments. *p <0.05.
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In this study, we investigated whether affibody molecules
targeting H-Ras or Raf-1 can inhibit cell proliferation
and the production of inflammatory mediators in vitro.
To date, it has been demonstrated that intracellularly
expressed affibody molecules can bind to target mole-
cules and inhibit their functions. For example, an affi-
body molecule that has an affinity for epidermal growth
factor receptor (EGFR) retains EGFR in the secretory
compartment. This constraint led to decreased phos-
phorylation of EGFR and a reduced proliferation rate
(Vernet et al. 2009). An affibody molecule targeting HER-
3 inhibits proliferation of a cancer cell line (Göstring et al.
2012). However, we demonstrated for the first time that
an affibody targeting intracellular signal transduction
molecules could inhibit cell proliferation and the pro-
duction of inflammatory mediators. We demonstrated
that H-Ras- (Zras122, Zras220, Zras521) or Raf-1- (Zraf322)
targeting affibody molecules inhibited the production of
IL-6 and PGE2 in a synovial cell line. These affibody
molecules were introduced into the cells via DNA-
encoding plasmids or as purified proteins. In both cases,
inhibition of IL-6 and PGE2 production was observed
for almost all affibody molecules.
Several previous reports indicated suppression of syn-
ovial cell function by Ras inhibition. For instance, genetransfer of a dominant negative mutant of the Ras gene
(Yamamoto et al. 2003) or gene silencing using a locked
nucleic acid against Ras (de Launay et al. 2010) in syn-
ovial cells inhibited the production of inflammatory me-
diators, such as IL-6. Consistent with these reports, we
observed that affibody molecules binding to H-Ras or
Raf-1 could inhibit the production of IL-6. PGE2 pro-
duction by RA synovial cells is regulated by Ras (Na
et al. 2004). Therefore, we analyzed PGE2 levels and
demonstrated that these affibody molecules also inhibited
PGE2 production. Matrix metalloproteinase (MMP)-3 is a
protease that is produced by synovial cells upon TNF-α
stimulation, and its production is regulated by Ras (Abreu
et al. 2009). We analyzed MMP-3 levels and demonstrated
that these affibody molecules also inhibited MMP-3 pro-
duction (data not shown). These results indicate that affi-
body molecules binding to H-Ras or Raf-1 can inhibit
inflammatory mediators or proteases, such as IL-6, PGE2,
and MMP-3, which are crucial to RA pathogenesis.
Regarding the expression of affibody molecules in MH7A
cells, we observed stronger expression of Zras122 than
other affibody proteins. In addition, Zras122 protein levels
increased, while Zraf322 and Zras521 protein levels decreased
between 24 and 48 h (Figure 1). These results might be re-
lated to the stability of the Zras122 affibody protein afforded
by the plasmid construct. Supporting this notion, we
AB
Figure 5 Cell proliferation assay for MH7A cells transfected with plasmid-expressed affibody molecules (A) and MH7A cells introduced
affibody molecules as protein (B). After 24 h of culture, the cells were stimulated with TNF-α (100 ng/mL) and cultured for an additional 24–48 h.
Cell proliferation was analyzed with a CCK assay. Data represent the means ± SD of three independent experiments. *p <0.05.
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by 23.9% and 26.2% relative to the control vector treat-
ment at 24 h, while these inhibitory effects were decreased
to 17.8% and 10.1% at 48 h after TNF-α stimulation,
respectively. In contrast, inhibition by Zras122 was main-
tained up to 48 h after TNF-α stimulation (Figure 2A),
suggesting increased stability of the affibody. With regard
to PGE2 production, inhibition by all affibodies at 48 h
increased compared with that at 24 h after TNF-α stimula-
tion. Of interest, the timing of maximal inhibition was
different for IL-6 and PGE2, but the underlying mechanism
is still unknown. The difference could be attributed to the
difference in the signal transduction cascade of these in-
flammatory molecules.
To determine whether affibody molecules inhibit signal
transduction via ERK, we examined the phosphorylation
of ERK1/2, a downstream molecule of Ras/Raf signaling.
Zras220 inhibited ERK1/2 phosphorylation in the early stage
(16 h) after stimulation by TNF-α (Figure 3), although we
did not observe distinct inhibition by other affibodies. This
transient inhibition of ERK1/2 phosphorylation might becaused relatively by Zras220 via interruption of the inter-
action between Raf-1 and MEK1/2 (Chen et al. 2001).
However, this inhibition on ERK1/2 phosphorylation
could not be kept after 16–24 h, so that differences
of phosphorylation among all affibody molecules here
should be investigate more precisely in further study.
We utilized two different methods to deliver affibody
molecules into synovial cells: 1) transfection of plasmids
encoding the affibody molecules and 2) introduction of
affibody proteins using a cell-penetrating peptide reagent.
Protein-introduced affibody molecules exhibited stronger
inhibition of IL-6 and PGE2 production than plasmid-
expressed affibody molecules (Figures 2 and 4). More-
over, the inhibition resulting from the introduced
proteins was less variable than that resulting from plas-
mid transfection. When cell proliferation was examined
using plasmid-encoded affibody molecules, distinctive
differences were not observed (Figure 5A). On the con-
trary, introduction of Zraf322 proteins partially inhibited
cell proliferation (Figure 5B), suggesting that a plasmid-
based expression system did not generate a sufficient
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nal transduction. In the experiments using plasmids,
cell proliferation was not observed at 24 (Figure 5A),
while in the experiments using proteins, cell prolifera-
tion was observed at the same period (Figure 5B). This
might be based on higher cytotoxicity of liposome com-
pared with peptides used as a carrier (Suhorutsenko et al.
2011). These results indicate that protein-introduced
affibody molecules more effectively inhibited cytokine
production and cell proliferation in synovial cells than
plasmid-expressed affibody molecules. Although the
effect on synovial cell proliferation was not strong, our
results demonstrate that it is possible to inhibit synovial
cell proliferation by selecting useful affibody clones and
by improving transduction efficiency of affibody protein
molecules.
Inhibition of IL-6 and PGE2 production caused by
the protein-introduced affibodies varied. For example,
at 48 h after TNF-α stimulation, inhibition of IL-6 pro-
duction was greater than 40% for three affibodies
(Zras122, Zras220, and Zras521), whereas that of PGE2 was
approximately 30% for two affibodies (Zras220 and
Zraf322). These results could be attributed to the fact
that the PGE2 receptor, which couples with G proteins,
is integrated into a positive feedback loop for PGE2
production (Nishimura et al. 2013); thus, the effect of
an affibody molecule on PGE2 production might be
weaker than on IL-6. The differential effectiveness of
each affibody molecule on synovial cell function might
also be explained by differences in the amino acid
sequences of the affibodies themselves. Each clone was se-
lected using a phage display library of Z variants, and the
amino acid sequences encoded by each clone are different.
In conclusion, we demonstrated that affibody mole-
cules could inhibit cell proliferation and the production
of inflammatory mediators by blocking the Ras/Raf
signal transduction cascade. Although inhibition of cell
function could be enhanced, and delivery methods should
be examined further, we propose that these molecules are
candidates to be investigated as a molecular-targeting
therapy for RA. Studies are in progress to select useful
affibody clones, to improve delivery methods of affibody
protein molecules, and to verify the efficiency of affibo-
dies in an RA model.Additional file
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